Patient enrolment concludes in Senhwa’s Phase Ib trial of pidnarulex

Senhwa Biosciences has completed enrolment in its Phase Ib expansion trial of pidnarulex as a monotherapy for people with advanced solid tumours carrying BRCA1/2 or partner and localiser of PALB2.

The post Patient enrolment concludes in Senhwa’s Phase Ib trial of pidnarulex appeared first on Hospital Management.

 

Back to the Featured Stories

Connect with us

Whether you are a professional looking for a new job or a representative of an organization who needs workforce solutions - we are here to help.